Vaccines as the primary growth engine (scale, pricing power, durability)

Leverage R&D platforms, manufacturing moat, and long product lifecycles

Core vaccines (shingles, RSV, meningococcal, pediatric combinations, travel)

Adjacent immunology/ID where synergistic (platform, channels, capabilities)

Expand adult immunization category

Deepen penetration in priority markets

Lifecycle management (LCM): new indications, label expansions, next-gen versions

Governments & National Immunization Programs (NIPs): tenders, public health goals, budgets

Payers / insurers: coverage, reimbursement, HTA

Providers: PCPs, pharmacists, nurses, clinics; hospitals, ID specialists, travel clinics

Employers / occupational health: workplace programs, productivity economics

Consumers / patients: self-pay/co-pay, health-conscious adopters

Age

Health status

Socioeconomic status: willingness/ability to pay, access, insurance

Respiratory (RSV, influenza-adjacent ecosystems)

Herpes zoster (shingles)

Meningococcal (ACWY/B): high-risk & travelers

Pediatric combination vaccines: adherence tied to schedules

Travel & endemic diseases: region-specific demand

Outbreak-prone / emerging pathogens: scenario-driven demand

High-income: reimbursement strength, adult immunization maturity, higher uptake potential

Upper-middle income: mixed public/private, expanding coverage, price sensitivity

Low & lower-middle income: donor/global alliance procurement, affordability constraints

Urban vs rural: provider density, cold-chain reach, clinic availability

Health engagement: preventive vs reactive

Vaccine confidence: pro-vaccine vs hesitant vs resistant

Channel preference: pharmacy convenience vs physician trust vs workplace clinics

Adherence behavior: multi-dose completion, follow-through

Fully reimbursed: broad access, volume-driven

Partially reimbursed: mixed influence

Self-pay: perceived value and marketing critical

Tender-based procurement: price/volume trade-offs

High efficacy and durability

Safety profile and tolerability (esp. older adults)

Single-visit solutions (simplified regimens)

Co-administration compatibility (flu/COVID/other adult vaccines)

Reliable supply and cold-chain robustness

Real-world evidence (RWE) and pharmacoeconomic value

Epidemiology-driven: highest burden, most preventable outcomes

Economics-driven: favorable reimbursement and willingness to pay

Capability-driven: differentiation in R&D, adjuvantation, manufacturing

Competitive intensity: defendable categories and white spaces

Feasibility: supply, regulatory timing, provider readiness

Older adults: adult immunization growth engine (shingles/RSV severity and value)

High-risk adults (immunocompromised / chronic disease): specialist and guideline-driven pathways

Pediatric schedule-based segments: stable demand via NIPs and routines

Travelers / region-specific risk groups: seasonal/destination-driven spikes

Government/NIP decision-makers: tender inclusion, schedule recommendations, rollout planning

Payers/HTA bodies: cost-effectiveness, budget impact, outcomes evidence

Providers (HCPs) as primary influencers

Employers/occupational health: large employers with measurable ROI

Anchor markets: strong adult vaccine reimbursement

Growth markets: expanding middle class, mixed private demand

Select public-health partnerships in lower-income settings (strategic + feasible)

Differentiated go-to-market by segment

Sequencing and resource allocation

Risk-based targeting: focus on highest hospitalization/complication risk segments

Science-led, innovation-driven vaccine leader with trusted supply and evidence

Public health impact + individual protection

For older adults: prevent severe outcomes, preserve independence/QoL, durable protection, strong RWE

For payers/governments: cost-offsets, budget predictability, supply commitments

For providers: robust data, clear guidance, easy administration, workflow fit, co-admin

For consumers: peace of mind, protect family, convenience (pharmacy access)

Innovation platforms (adjuvants, antigen design, next-gen formulations)

Evidence leadership (RWE, health economics, comparative evidence)

Manufacturing scale and supply reliability

LCM and indication expansion

Partnerships (pharmacies, health systems, public health agencies)

Public sector: population outcomes, equity, supply assurance, feasibility

Private payers: ROI, risk reduction, utilization alignment

HCPs: clinical data, safety, patient selection, administration guidance

Patients: benefit clarity, side-effect expectations, access points, reminders

Normalize routine adult vaccination beyond seasonal flu

Education via providers and pharmacy channels

Improve completion rates and boosters (where relevant)

Evidence-based hesitancy reduction

Expand access points (pharmacy, workplace, community clinics)

Reminder/recall and digital scheduling

New age bands, risk groups, co-administration labels

Next-gen formulations (duration, tolerability, dosing)

Combination opportunities (scientifically and commercially viable)

Value-based pricing aligned to burden/outcomes

Tiered pricing by country income level (where appropriate)

Tender contracting: volume commitments, multi-year agreements

Clinical trials → HTA → reimbursement → uptake → RWE → expanded recommendations

Post-marketing surveillance to maintain trust and address safety narratives

Capacity planning for launch peaks and seasonal demand

Cold-chain and distribution excellence

Risk management: redundancy, quality systems, regulatory compliance

Large vaccine incumbents: broad portfolios, tender strength

Biotech entrants: single-asset innovation, partnership-led scaling

Local manufacturers: cost advantage in select markets

Efficacy, safety/tolerability, dosing convenience, duration

Price and tender competitiveness

Supply reliability at national volumes

Label breadth and guideline endorsements

Defend leadership in established adult indications

Expand in fast-growing respiratory and adult categories

Pre-empt via LCM and real-world evidence

Stakeholder mapping: ministries, advisory committees, procurement agencies

Tender strategy: pricing corridors, supply commitments, multi-year bids

Implementation support: training, logistics, monitoring metrics

Preferred partnerships, pharmacist training, in-store awareness

Convenience positioning: walk-in availability, extended hours

Data-sharing for adherence and reminders

Clinical pathways and standing orders

Co-administration protocols and workflow tools

CME and scientific education via medical affairs

On-site clinics, seasonal campaigns, bundled respiratory messaging

ROI dashboards (absenteeism, utilization proxies)

Eligibility checkers, booking, reminders

Tailored messaging for hesitant segments

Segment uptake, coverage %, dose volumes

Share within indication and by channel (pharmacy vs physician)

Time-to-reimbursement, formulary wins, tender success

Net price realization vs plan, contract renewal rates

Guideline inclusions, HTA outcomes, RWE publications

Safety signal monitoring and response time

HCP recommendation rates, reach/frequency, conversion by segment

Appointment completion and series adherence

Fill rates, stock-outs, cold-chain excursions, batch release timeliness